Laser-engineered dissolving microneedle arrays for protein delivery: Potential for enhanced intradermal vaccination

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 3, 2015, Pages 409-425

  McCrudden, Maelíosa T C ^a   Torrisi, Barbara M ^a   Al Zahrani, Sharifah ^a   McCrudden, Cian M ^a   Zaric, Marija ^b   Scott, Christopher J ^a   Kissenpfennig, Adrien ^b   McCarthy, Helen O ^a   Donnelly, Ryan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Infection and Immunity   (United Kingdom)

Author keywords

laser engineering; microneedles; protein delivery; vaccination

Indexed keywords

GAMMA INTERFERON; GANTREZ COPOLYMER; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; OVALBUMIN; ANTIGEN; ETHER DERIVATIVE; IL4 PROTEIN, HUMAN; MALEIC ACID; MALEIC ACID DERIVATIVE; POLY(VINYL METHYL ETHER); POLYVINYL DERIVATIVE; VACCINE;

ANAPHYLACTIC SHOCK; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISSOLVING MICRONEEDLE ARRAY; DRUG SOLUBILITY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MICRONEEDLE; MOUSE; NEEDLE; NEWBORN; NONHUMAN; RESPIRATORY TRACT INFLAMMATION; SKIN PERMEABILITY; SPLEEN CELL; STRATUM CORNEUM; SWINE; SYRINGE; ANIMAL; BLOOD; CHEMISTRY; DRUG DELIVERY SYSTEM; INTRADERMAL DRUG ADMINISTRATION; LASER; METABOLISM; MICROINJECTION; PROCEDURES; SKIN; SKIN ABSORPTION; SOLUBILITY; VACCINATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; INTERFERON-GAMMA; INTERLEUKIN-4; LASERS; MALEATES; METHYL ETHERS; MICE; MICROINJECTIONS; NEEDLES; OVALBUMIN; POLYVINYLS; SKIN; SKIN ABSORPTION; SOLUBILITY; VACCINATION; VACCINES;

EID: 84925616816     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12248     Document Type: Article

References (64)

1. Donnelly RF, et al. Microneedle-Mediated Transdermal and Intradermal Drug Delivery. New Jersey: John Wiley & Sons, 2012.
2. Ito Y, et al. Transdermal insulin application system with dissolving microneedles. Diabetes Technol Ther 2012; 14: 891-899.
3. Liu S, et al. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. J Control Release 2012; 161: 933-941.
4. Donnelly RF, et al. Processing difficulties and instability of carbohydrate microneedle arrays. Drug Dev Ind Pharm 2009; 35: 1242-1254.
5. Lee JW, et al. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008; 29: 2113-2124.
6. Gomaa YA, et al. Laser-engineered dissolving microneedles for active transdermal delivery of nadroparin calcium. Eur J Pharm Biopharm 2012; 82: 299-307.
7. Matsuo K, et al. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. J Control Release 2012; 161: 10-17.
8. Naito S, et al. Antigen-loaded dissolving microneedle array as a novel tool for percutaneous vaccination. Vaccine 2012; 30: 1191-1197.
9. Matsuo K, et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J Control Release 2012; 160: 495-501.
10. Sullivan SP, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16: 915-920.
11. Pattani A, et al. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J Control Release 2012; 162: 529-537.
12. Hiraishi Y, et al. Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system. Int J Pharm 2013; 441: 570-579.
13. Garland MJ, et al. Dissolving polymeric microneedle arrays for electrically assisted transdermal drug delivery. J Control Release 2012; 159: 52-59.
14. Zaric M, et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. Photodiagnosis Photodyn Ther 2010; 7: 222-231.
15. Donnelly RF, et al. Microneedle-mediated intradermal nanoparticle delivery: potential for enhanced local administration of hydrophobic pre-formed photosensitisers. Anal Biochem 2001; 290: 179-185.
16. Donnelly RF, et al. Design, optimization and characterization of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique. Pharm Res 2011; 28: 41-57.
17. Woolfson AD, et al. Moisture-activated, electrically conducting bioadhesive hydrogels as interfaces for bioelectrodes: effect of film hydration on cutaneous adherence in wet environments. J Appl Polym Sci 1995; 58: 1291-1296.
18. Fourtanier A, Berrebi C,. Miniature pig as an animal model to study photoaging. Photochem Photobiol 1989; 50: 771-784.
19. Rolland JM, et al. Specific and sensitive enzyme-linked immunosorbent assays for analysis of residual allergenic food proteins in commercial bottled wine fined with egg white, milk, and nongrape-derived tannins. J Agric Food Chem 2007; 56: 349-354.
20. Donnelly RF, et al. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution. J Control Release 2010; 147: 333-341.
21. Bouchard M, et al. Formation of insulin amyloid fibrils followed by FTIR and simultaneously with CD and electron microscopy. Protein Sci 2000; 9: 1960-1967.
22. Henricus MM, et al. Investigation of insulin loaded self-assembled microtubulus for drug release. Bioconjug Chem 2008; 19: 2394-2400.
23. Chen MC, et al. Chitosan microneedle patches for sustained transdermal delivery of macromolecules. Biomacromolecules 2012; 13: 4022-4031.
24. Sullivan SP, et al. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater 2008; 20: 933-938.
25. Kommareddy S, et al. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci 2012; 101: 1021-1027.
26. Lee JW, et al. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 2011; 7: 531-539.
27. Lee JW, et al. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008; 29: 2113-2124.
28. Sun W, et al. Polyvinylpyrrolidone microneedles enable delivery of intact proteins for diagnostic and therapeutic applications. Acta Biomater 2013; 9: 7767-7774.
29. Park JH, et al. Polymer microneedles for controlled-release drug delivery. Pharm Res 2006; 23: 1008-1019.
30. Wangoo N, et al. Interaction of gold nanoparticles with protein: a spectroscopic study to monitor protein conformational changes. App Phys Lett 2008; 92: 133104-1-133104-3.
31. Migalska K, et al. Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery. Pharm Res 2011; 28: 1919-1930.
32. Zaric M, et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano 2013; 7: 2042-2055.
33. Verbaan FJ, et al. Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin. J Controlled Release 2007; 117: 238-245.
34. Zhao W, Yang R,. Pulsed electric field induced aggregation of food proteins: ovalbumin and bovine serum albumin. Food Bioprocess Technol 2012; 5: 1706-1714.
35. Beisson F, et al. Use of the tape stripping technique for directly quantifying esterase activities in human stratum corneum. Anal Biochem 2001; 290: 179-185.
36. Engelrud T,. Stratum corneum chymotryptic enzyme: evidence of its location in the stratum corneum intercellular space. Eur J Dermatol 1992; 2: 50-55.
37. Huang Y, Wu S,. Stability of peptides during iontophoretic transdermal delivery. Int J Pharm 1996; 131: 19-23.
38. Ballin NZ, Lametsch R,. Analytical methods for authentication of fresh vs thawed meat-A review. Meat Sci. 2008; 80: 151-158.
39. Mathers AR, Larregina AT,. Professional antigen-presenting cells of the skin. Immunol Res 2006; 36: 127-136.
40. Andrews SN, et al. Transdermal delivery of molecules is limited by full epidermis, not just stratum corneum. Pharm Res 2013; 30: 1099-1109.
41. Sauder DN,. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-S11.
42. Koutsonanos DG, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 2009; 4: e4773.
43. Romani N, et al. Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 2010; 88: 424-430.
44. Shakya AK,. Polymers as immunological adjuvants: an update on recent developments. J BioSci Biotech 2012; 3: 199-210.
45. Wang W, Singh M,. Selection of adjuvants for enhanced vaccine potency. World Journal of Vaccines 2011; 1: 33-78.
46. De Souza Rebouças J, et al. Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol 2012, in press. ID 474605.
47. Rebouças JDS, et al. Development of poly(anhydride) nanoparticles loaded with peanut proteins: the influence of preparation method on the immunogenic properties. Eur J Pharm Biopharm 2012; 82: 241-249.
48. Sullivan S, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16: 915-920.
49. Vermeulen M, et al. Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells. J Immunol 2004; 172: 3196-3204.
50. Bal SM, et al. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 2010; 148: 266-282.
51. Weldon WC, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS ONE 2012; 7: 1-8.
52. Petrovsky N, Aguilar JC,. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-496.
53. Stübgen JP,. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev 2014; 13: 31-39. doi: 10.1016/j.autrev.2013.08.005; [Epub 2013 Aug 31].
54. Goldstein D, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998; 178: 858-861.
55. Smits ELJM, et al. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008; 13: 859-875.
56. Schulte S, et al. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol 2008; 172: 1500-1508.
57. Taylor JM, et al. Effects of a Th1- vs a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog 2008; 44: 20-27.
58. Berger A,. Science commentary: Th1 and Th2 responses: what are they? BMJ 2000; 321: 424.
59. Maloy K, et al. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly (lactide-co-glycolide) microparticles. Immunology 1994; 81: 661-667.
60. Banner KH, et al. Ovalbumin challenge following immunization elicits recruitment of eosinophils but not bronchial hyperresponsiveness in guinea-pigs: time course and relationship to eosinophil activation status. Pulm Pharmacol 1996; 9: 179-187.
61. Wegmann M,. Animal models of chronic experimental asthma-strategies for the identification of new therapeutic targets. J Occup Med Toxicol 2008; 3: 1-5.
62. Choi JR, et al. Apigenin protects ovalbumin-induced asthma through the regulation of GATA-3 gene. Int Immunopharmacol 2009; 9: 918-924.
63. McCaskill A, et al. Anaphylaxis following intranasal challenge of mice sensitized with ovalbumin. Immunology 1984; 51: 669-677.
64. Roman B, et al. Intradermal immunization with ovalbumin-loaded poly-ε-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice. Clin Exp Allergy 2007; 37: 287-295.